David Maloney, MD

Professor of Medicine
University of Washington


1991, PhD, Stanford University, Stanford, CA (Cancer Biology)
1985, MD, Stanford University, Stanford, CA

Research Focus:

Improving treatments for patients with CLL, lymphoma and myeloma by increasing activity and decreasing toxicity:

  • Development and use of anti-CD19 chimeric antigen receptor modified T –cells as treatment for B cell lymphoma, CLL and ALL (CAR-T).
  • Development and use of reduced intensity conditioning regimens for allogeneic stem cell transplantation for CLL, lymphoma and myeloma.
  • Augmenting allogeneic transplantation with targeted agents with greater specificity for tumor cells.
  • Understanding the mechanism of action of monoclonal antibodies used for the treatment of CLL and NHL.
  • Addition of radioimmunotherapy to autologous or allogeneic stem cell transplantation.

Clinical Expertise:

  • Treatment of lymphoma
  • Treatment of CLL
  • Treatment of myeloma
  • Allogeneic transplantation with reduced intensity conditioning for NHL, CLL and myeloma
  • Autologous transplantation for lymphoma and myeloma

Current Studies:

Protocols currently enrolling participants include:

2639: Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor

1409: A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-Myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi-Center Trial

2522: Head to Head Trial of Ofatumumab versus Rituximab – A Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

2560: Maintenance Therapy with Brentuximab Vedotin (SGN-35) after Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma and CD30+ Hematologic Malignancies

David Maloney, MD

Contact Information

(206) 667-5616
(206) 667-6124
Additional contact

Mail Stop: D1-100